Observation of botulinum toxin type A in children with upper limb spastic cerebral palsy Nervous System Diseases
Conditions
Interventions
The participants will be aged between 4 and 18 years old, will have been diagnosed with spastic cerebral palsy in their upper limb and will be due to start BTX-A treatment for their hand, wrist or for
Sponsors
Imperial College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged between 4 and 18 years old 2. Diagnosed with spastic cerebral palsy in at least one of their upper limbs 3. Due to start BTX-A treatment for their affected upper limb 4. Minimum ability to hold an object and stabilise it for use by the other hand 5. Able to comprehend and complete the test protocol 6. Participant or the participants' parent/carer must be able to speak, read and understand English, in order to be involved in this study
Exclusion criteria
Exclusion criteria: 1. Any surgical intervention on the upper extremity in the last 6 months 2. Any known allergy to adhesives 3. Any known skin allergies 4. Unable to obtain informed consent from participant's parent/carer 5. The participant and the participants' parent/carer are not able to speak, read and understand English
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Elastic and architectural properties of muscles and tendons in children with upper limb spastic cerebral palsy measured using ultrasound before the start of intramuscular botulinum toxin type A (BTX-A) injections, between 3 weeks and 3 months after treatment and at least 6 months after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscle activity during the Modified Ashworth scale test measured using electromyography sensors placed on the upper limb before intramuscular BTX-A injections, between 3 weeks and 3 months after treatment and at least 6 months after treatment | — |
Countries
England, United Kingdom
Contacts
Public ContactTaiwo Kelani
Outcome results
None listed